Continuous Glucose Monitoring Among Individuals With Gestational Diabetes Treated With Metformin Versus Insulin: Protocol for a Nested Prospective Cohort in the DECIDE RCT (DECIDE CGM)
The DECIDE CGM study, sponsored by Ohio State University, aimed to evaluate the effectiveness of Continuous Glucose Monitoring (CGM) in managing gestational diabetes treated with Metformin compared to Insulin. The study's withdrawal indicates a strategic focus on the parent DECIDE trial, which may impact the development of CGM technologies in this therapeutic area. The market for diabetes management, particularly in pregnancy, remains competitive with significant players like Dexcom, Inc. and Abbott Laboratories. The findings from the parent trial could influence treatment protocols and market positioning for both Metformin and Insulin in GDM management, as well as CGM device adoption in clinical practice.
Indication: Gestational Diabetes Mellitus
Modality: medical device
Target: Continuous Glucose Monitoring (CGM) metrics in individuals with Gestational Diabetes Mellitus (GDM) treated with Metformin versus Insulin.
Sponsor: Ohio State University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Continuous Glucose Monitoring (CGM) metrics in individuals with Gestational Diabetes Mellitus (GDM) treated with Metformin versus Insulin.
View original source fields
Condition raw: Gestational Diabetes Mellitus, Pregnancy, High Risk
Condition normalized: Gestational Diabetes Mellitus, Pregnancy, High Risk
Modality raw: medical device
Modality normalized: medical device
Target raw: Continuous Glucose Monitoring (CGM) metrics in individuals with Gestational Diabetes Mellitus (GDM) treated with Metformin versus Insulin.
Target normalized: Continuous Glucose Monitoring (CGM) metrics in individuals with Gestational Diabetes Mellitus (GDM) treated with Metformin versus Insulin.